
Navigating the Seattle startup ecosystem: A guide for Microsoft and Amazon execs
Since I left Microsoft in May, I have been inundated by Microsoft executives and employees wanting to explore and engage in the Seattle startup ecosystem. Prior to joining Microsoft, I always wondered why I would never see Microsoft or Amazon employees at startup events. Now I know Microsoft is its own all consuming ecosystem, where internal networking can be way more important than external networking.
Here's a guide on how Microsoft and Amazon employees can get involved in the Seattle tech scene, with limited time commitments.
Engage as an advisor or board member
Advising startups is a common way to contribute your expertise. Generally, in my experience, advisor positions are not a big time commitment, often involving meetings once a month or every couple of months initially. Your involvement may decline once a company raises venture capital unless your expertise is highly specific to their needs.
Compensation: Advisor compensation typically ranges from 0.1% up to 1% of the company's stock with the median grant of 0.25%, depending on the stage, your engagement, your expertise and chemistry with the founding team. Peter Walker of Carta does a good breakdown on LinkedIn.
Board roles: Becoming a board member often occurs after a startup's first round of financing, with venture capital firms seeking outside perspectives. They look for specific expertise that investors are not going to add — like unique industry or technology insights, go-to-market strategies, sales and marketing, or finance. Later stage startups will often hire 'been there done that' CEOs or CFOs who can add credibility or guidance for a startup as they prepare to go public or be acquired.
Strategic investing in startups
There are two primary paths for investing:
Direct angel investing
This is a hands-on approach. Angel investing is a lot of work! A successful angel investor like Ron Conway in Silicon Valley can make a lot of money by being early to investing and then introducing startups to venture capital firms. To potentially make money, I believe you need to consistently invest in at least 20+ companies over four to five years, making four-to-five investments a year. The vast majority of these startups will fail, but you will start to see some success. Over that time period, you will build your reputation in the market as an investor, start learning what to look for, and then entrepreneurs can start coming to you for advice and funding.
Seed funds
Personally, I don't have the time to commit to angel investing, but I want to support my fellow Seattle entrepreneurs and support the Seattle ecosystem. I have made investments in Seattle seed funds which are venture capital firms investing in Seattle entrepreneurs at the earliest stages of the journey. Many of these firms will entertain smaller funds, instead of $1 million minimum at more established funds. Seattle seed funds also value the local network and expertise to help develop their portfolio companies. Larger funds often have venture partners and deep industry relationships, when smaller funds do not.
Some notable Seattle pre-seed and seed funds are:
Unlock Venture Partners
Ascend
Founders' Co-op
AI2 Incubator
Flying Fish Partners
Two Ravens VC
Pioneer Square Labs
Madrona
Voyager Capital
FUSE
Maveron
Tola Capital
Second Avenue Partners
Seed funds are known for building a community around entrepreneurs and their investors. You can choose how involved you want to be. Most seed funds welcome investors with experience (particularly in enterprise and AI). You can mentor founders and help with the go-to-market and build a network across their investors as well. It's been a great way for me to stay relevant in the market and keep expanding my network.
Expected returns & risks
The goal for most venture capital firms is to achieve at least a 20% internal rate of return (IRR) or greater. Venture investments are highly speculative, with 90% typically failing and fund returns can vary significantly. For example, a fund's first fund might track 2-3X returns, while others might be flat or lose money.
Diversification across multiple funds is crucial to mitigate risk. Seed funds are considered the earliest and riskiest stage of venture capital. Large public investment firms like CALPERS, Washington State Investment Board, and the University of California publicly report many of the investment returns for private equity and venture capital firms. You can see the broad spread of returns based on the firm.
Diversification and getting into the 'right' funds for the right vintage (i.e. the right year) is often key to success. It is easier to make money in a rising tide environment.
Networking and finding opportunities
The most important thing is getting started! Instead of sitting on Teams meetings in Redmond or South Lake Union, just get started by attending some events. My rule of thumb is that I am willing to go to any event where I think I can meet one person with whom I will do business in the future. I also try to meet at least one new person I have never met before at every event.
Meet people who are moving and shaking in the startup scene – would be entrepreneurs, co-founders, entrepreneurs, the startup curious, angel investors, incubators, seed funds and the service providers like the lawyers that work with start-ups like Perkins Coie, Wilson Sonsini, Fenwick & West, DLA Piper, and Cooley LLP. Law firms often have a finger on the earliest stages of the startup journey.
Below are a number of organizations that regularly host startup get togethers for the Seattle community:
AI2 Incubator
TiE Seattle
Pioneer Square Labs
Foundations
GeekWire
Seattle Tech Week
Ascend's Founder Bash
Get started!
The Seattle startup ecosystem offers great learning, networking and potential investment opportunities. Plus you can give back and contribute to the growth of the next Amazon or Microsoft right here in our backyard.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a minute ago
- Yahoo
Apple's (AAPL) AI Strategy Falls Short, Says Barclays—Is the Stock Still a Must-Watch?
Apple Inc. (NASDAQ:AAPL) is one of the . On July 29, Barclays said it remains cautious on Apple, maintaining its 'Underweight' rating. The analyst highlighted factors such as limited traction on artificial intelligence and risks around tariffs, China, and regulation. The firm said that it anticipates 'a slight June-Q beat led by better FX, iPhone and Mac upside,' helped by tariff-related pull-in. It isn't very optimistic on the stock due to a lack of progress. 'We still see no major progress on AI for AAPL.' Particularly discussing Apple's innovations at the annual developer conference, the firm said that the conference 'underwhelmed with the AI feature announcements, viewing them as more evolutionary than revolutionary.' It further added that 'The reception of Apple Intelligence has also been disappointing.' The firm believes Apple's long-term AI strategy remains muddy and that its light weight approach to AI may or may not be enough to drive an upgrade cycle or growth. Barclays also talked about tariffs, stating that '2H GM remains a wildcard with lack of clarity on tariffs and mitigation efforts.' Apple is a technology company known for its consumer electronics, software, and services. While we acknowledge the potential of AAPL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Must-Watch AI Stocks on Wall Street and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a minute ago
- Yahoo
Biogen Lifts Outlook As Rare Disease And Alzheimer's Drug Sales Accelerate
Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% year over year, beating the analyst consensus of $4.06. The company reported sales of $2.65 billion, up 7% year over year on a reported basis, 8% on constant currency, beating the consensus of $2.32 billion. Multiple sclerosis revenue of $1.1 billion decreased by 4% (down 4% on constant currency). Sales of the multiple sclerosis drug Tysabri were down to $454.6 million from $462.2 disease revenue increased 2% year over year (up 3% on constant currency) to $543 million. Spinraza's revenue decreased to $392.7 million from $429.1 million a year ago. Revenues from Skyclarys, acquired via the Reata acquisition, reached $130.3 million during the quarter, up from $100 million a year ago, showing continued growth in demand; U.S. SKYCLARYS revenue of approximately $78 million represents sequential growth of 13%. In Alzheimer's disease, Biogen said Leqembi's U.S. in-market sales of approximately $63 million represent sequential growth of 20%. Global in-market sales of approximately $160 million include a one-time shipment to China of approximately $35 million to optimize global inventory levels. Clinical data presented at AAIC demonstrate that four years of continuous treatment with Leqembi benefits early Alzheimer's patients, including low tau patients, who continue to see sustained improvements in cognitive and daily living function. Outlook Biogen raised its 2025 adjusted earnings guidance from $14.50-$15.50 per share to $15.50-$16.00, compared to the consensus of $14.98. View more earnings on BIIB The updated guidance reflects an 87 cents benefit from an expected stronger business outlook for the full year, partially offset by the ~($0.12) impact from the City Therapeutics transaction. The company expects total revenue for the full year 2025 to be approximately flat, at constant currency, versus the full year 2024, which is up from a mid-single digit decline previously. The outlook reflects the strong first-half revenue performance, including the resilient performance of the U.S. multiple sclerosis business. Biogen expects increased competitive pressures on the ex-U.S. multiple sclerosis business in the second half of 2025, particularly for Tecfidera in Europe. Due to planned plant maintenance activities, Biogen expects minimal contract manufacturing revenue in the fourth quarter of 2025. Potential tariffs, even if the current exemption for pharmaceuticals ends, are not expected to affect the company's 2025 financial outlook. The Fit for Growth program is expected to generate approximately $1 billion of gross savings and $800 million net of reinvestment by the end of 2025. In 2025, Biogen plans to make additional investments in R&D, primarily to support rare diseases. Biogen expects combined Non-GAAP R&D expense and Non-GAAP SG&A expense to total approximately $4 billion in 2025. Price Action: BIIB stock is trading higher by 3.01% to $130.45 at last check Thursday. Read Next:Photo by JHVEPhoto via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? BIOGEN (BIIB): Free Stock Analysis Report This article Biogen Lifts Outlook As Rare Disease And Alzheimer's Drug Sales Accelerate originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a minute ago
- Yahoo
Tether Posts $4.9B Profit, Surpasses $127B In U.S. Treasuries In Q2
Tether (CRYPTO: USDT) on Thursday released its Q2 2025 attestation, showing the company added over $13.4 billion in USDT during the quarter. What Happened: With more than $20 billion in net new issuance year-to-date, the total supply of USDT has risen to over $157 billion. The report shows that Tether's total exposure to U.S. Treasuries climbed to $127 billion, including $105.5 billion in direct holdings and $21.3 billion held indirectly, up from roughly $119 billion in Q1. This level of exposure places Tether among the world's largest holders of U.S. sovereign debt, rivaling even institutional investors and central banks. Tether's net profit for the second quarter reached approximately $4.9 billion, with $3.1 billion of that attributed to recurring operational earnings. The remainder, roughly $1.8 billion, came from mark-to-market appreciation in its bitcoin and gold holdings. Combined with Q1 results, total net profit for the first half of 2025 now stands at $5.7 billion. Shareholder capital remained steady at around $5.47 billion, supporting Tether's long-term solvency. The attestation confirmed that Tether's total assets stood at $162.57 billion at the end of June, exceeding its $157.1 billion in liabilities, of which $157.1 billion were related to tokens issued. Tether noted that proprietary investments in emerging sectors such as AI, energy, and communications are not counted as part of its token reserves. However, these ventures, led through Tether Investments and XXI Capital, continue to receive a growing share of Tether's retained earnings. The firm reported that roughly $4 billion has already been deployed into U.S.-based ventures as part of its reinvestment strategy, including projects like Rumble and the Rumble Wallet. These initiatives are aimed at enhancing financial infrastructure, digital rights, and open-source platforms globally. Also Read: What's Next: CEO Paolo Ardoino emphasized growing confidence in Tether's model, stating, "Q2 2025 affirms what markets have been telling us all year: trust in Tether is accelerating." "With over $127 billion in U.S. Treasury exposure, robust Bitcoin (CRYPTO: BTC) and gold reserves, and over $20 billion in new USDT issued, we're not just keeping pace with global demand, we're shaping it,' he added. Ardoino also noted that Tether represents a "live, proven model" of stablecoin functionality at scale, offering "transparency, resilience, and massive global reach" amid ongoing regulatory developments concerning digital dollars. Read Next: Image: Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Tether Posts $4.9B Profit, Surpasses $127B In U.S. Treasuries In Q2 originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data